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Abstract
Background: Osteosarcomas are the most common primary malignant tumors of bone, showing complex
chromosomal rearrangements with multiple gains and losses. A frequent deletion within the chromosomal region
3q13.31 has been identified by us and others, and is mainly reported to be present in osteosarcomas. The purpose
of the study was to further characterize the frequency and the extent of the deletion in an extended panel of
osteosarcoma samples, and the expression level of the affected genes within the region. We have identified LSAMP
as the target gene for the deletion, and have studied the functional implications of LSAMP-reexpression.
Methods: LSAMP copy number, expression level and protein level were investigated by quantitative PCR and
western blotting in an osteosarcoma panel. The expression of LSAMP was restored in an osteosarcoma cell line, and
differences in proliferation rate, tumor formation, gene expression, migration rate, differentiation capabilities, cell
cycle distribution and apoptosis were investigated by metabolic dyes, tumor formation in vivo, gene expression
profiling, time-lapse photography, differentiation techniques and flow cytometry, respectively.
Results: We found reduced copy number of LSAMP in 45/76 osteosarcoma samples, reduced expression level in
25/42 samples and protein expression in 9/42 samples. By restoring the expression of LSAMP in a cell line with a
homozygous deletion of the gene, the proliferation rate in vitro was significantly reduced and tumor growth in vivo
was significantly delayed. In response to reexpression of LSAMP, mRNA expression profiling revealed consistent
upregulation of the genes hairy and enhancer of split 1 (HES1), cancer/testis antigen 2 (CTAG2) and kruppel-like
factor 10 (KLF10).
Conclusions: The high frequency and the specificity of the deletion indicate that it is important for the
development of osteosarcomas. The deletion targets the tumor suppressor LSAMP, and based on the functional
evidence, the tumor suppressor function of LSAMP is most likely exerted by reducing the proliferation rate of the
tumor cells, possibly by indirectly upregulating one or more of the genes HES1, CTAG2 or KLF10. To our knowledge,
this study describes novel functions of LSAMP, a first step to understanding the functional role of this specific
deletion in osteosarcomas.
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Background
Osteosarcomas are the most common primary malignant
tumors of bone. They are highly aggressive with poor
prognosis [1,2] and occur most frequently in children and
adolescents [3]. The efficacy of the current treatments has
reached a plateau, and the need of increased biological un-
derstanding is crucial to improve treatment options and
thus the life of patients.
At the genomic level, osteosarcomas show complex
chromosomal rearrangements with multiple gains and
losses [4,5]. Array comparative genomic hybridization
(aCGH) has been used extensively to analyze DNA copy
number changes at a higher resolution, identifying recur-
rent chromosomal alterations [6-11]. We have previously
identified a novel, frequent deletion in 3q13.31 in osteosar-
comas [6]. Of the genes located within the deleted region,
three have been proposed to be involved in cancer biology:
the protein-coding gene limbic system-associated mem-
brane protein (LSAMP) and the two non-coding RNAs
LSAMP RNA antisense 3 (LSAMP-AS3) (also known as
LOC285194 or TUSC7) and LSAMP RNA antisense 4
(LSAMP-AS4) (also known as BC040587) [6,12-20].
LSAMP has previously been reported to be a candidate
tumor suppressor gene in clear cell renal cell carcinoma
and epithelial ovarian cancer [15-17], and subsequently
also in osteosarcomas [6,12-14]. All three of these genes
have also been proposed to act in conjunction as tumor
suppressors in osteosarcomas [13].
In this study, the frequency and extent of the dele-
tion and the aberrations of LSAMP were further investi-
gated. To study the potential importance of LSAMP in
osteosarcoma biology, we have examined the functional
implications of LSAMP-reexpression in an osteosarcoma
cell line with a homozygous deletion of the gene.
Results
The deletion in 3q13.31 targets LSAMP
In order to precisely define the deletion in 3q13.31, high-
resolution DNA copy number data obtained using Affy-
metrix Genome-Wide Human SNP Array 6.0 on a total of
76 osteosarcoma samples (32 clinical samples, 25 xeno-
graft samples and 19 cell lines) ([21,22] and Kresse et al.,
unpublished) were investigated. We determined the min-
imal recurrent deletion to be from chr3:116,560,000-
116,577,000 and present in 59% (45/76) of the samples
(Figure 1), with a similar distribution across the different
sample types (56% of the clinical samples (18/32), 64% of
the xenograft samples (16/25) and 58% of the cell lines
(11/19)). No differences were observed among the differ-
ent osteosarcoma subtypes investigated, although the ma-
jority of the samples were of osteoblastic subtype (subtype
information in Additional file 1: Table S1). The high fre-
quency suggests that loss of 3q13.31 is important for de-
velopment of osteosarcoma, and that the region may
harbor tumor suppressor gene(s).
The number of annotated genes within the deleted re-
gion differs between the two databases ENSEMBL and
RefSeq, with the newly published ENCODE/GENCODE
data (version 17) supporting the ENSEMBL annotation
(Figure 1). Within the deleted region (chr3:116,000,000-
117,500,000), there are two genes commonly annotated
by both databases; LSAMP and LSAMP-AS3 (or TUSC7)
(Figure 1). To investigate whether loss of other genes
besides LSAMP could be important, we performed gene
Figure 1 Chromosome map and frequency plot of the observed deletions in 3q13.31 in osteosarcoma samples (n = 76). The shaded
gray area (chr3:116,269,000-116,896,000) corresponds to a frequency of≥ 30% of the samples. Below the frequency plot are the genes within
3q13.31 annotated by the databases ENSEMBL (red) and RefSeq (blue), and supporting annotation by ENCODE/GENCODE data (green).
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expression analysis of LSAMP RNA antisense 1 (LSAMP-
AS1), LSAMP-AS3 and LSAMP-AS4 in a panel of 5 osteo-
sarcoma clinical samples, 13 xenograft samples, 19 cell
lines and 14 control samples (n = 51). Expression of
LSAMP-AS1 was detected in 30/51 samples, with a similar
level between the osteosarcoma samples and the control
samples (Additional file 2: Figure S1). Furthermore, since
LSAMP-AS1 is located in the flanking region of the dele-
tion (Figure 1), it was excluded from further experiments.
Low expression of LSAMP-AS3 was detected in 5/46 sam-
ples, independent of the DNA copy number status, but not
in any of the control samples (Additional file 2: Figure S1).
Expression of LSAMP-AS4 was not detected in any of
the samples, cancer nor control (0/42) (Additional file 2:
Figure S1). In comparison, expression of LSAMP was
detected, although in variable amounts, in 43/49 of these
samples, including all the control samples ([6] and
Barøy et al., unpublished). These results indicate that
the deletion in 3q13.31 is not inactivating any of the
genes LSAMP-AS1, LSAMP-AS3 or LSAMP-AS4, but
rather that the expression level, or lack thereof, is a nor-
mal state for both non-cancerous and cancerous cells.
Thus, LSAMP is most likely the target gene for the
deletion.
Aberrations of LSAMP
Aberrations of LSAMP were investigated at the copy
number, expression and protein level (Figure 2A) in 42
osteosarcoma samples (8 clinical samples, 13 xenografts
and 21 cell lines). The copy number and expression level
Figure 2 LSAMP aberrations and patient survival. A: The correlation between LSAMP copy number, expression level and protein level in
osteosarcoma samples (n = 42). The samples are sorted according to their copy number (reduced, normal or gain). The relative expression level was
measured by qRT-PCR using two probes to cover the length of the gene (located in exon junction 1–2 and 6–7). No detectable expression level is
indicated with an asterisk (*). The corresponding LSAMP protein level was determined using western blot, with β-actin as loading control.
B: Kaplan-Meier plot showing overall survival for patients with loss (n = 6) and normal/gain (n = 12) of LSAMP copy number. C: Kaplan-Meier plot showing
overall survival for patients with low (n = 11) and high (n = 7) expression of LSAMP, compared to the average expression of two normal bone samples.
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of all the cell lines, except CAL 72 and G-292, have been
determined previously using aCGH and qRT-PCR, re-
spectively [6]. The copy number and expression levels of
the remaining samples were determined using TaqMan
DNA Copy Number Assay and qRT-PCR, respectively.
In total, 16/42 (38%) of the samples had reduced copy
number, 16/42 (38%) had normal copy number and 10/
42 (24%) had increased copy number. There were no
differences between sample types or osteosarcoma sub-
types. Of the 16 samples with loss of copy number, 11
samples had no or lower expression of LSAMP com-
pared to the average expression level of two normal
bone samples, detected by at least one of the probes
(Figure 2A). Of the 16 samples with normal copy num-
ber, 9 samples had lower expression of LSAMP detected
by at least one of the probes. Of the 10 samples with in-
creased copy number, 5 samples had lower expression of
LSAMP detected by at least one of the probes, indicating
that copy number aberrations might not be the only
mechanism regulating the expression level of LSAMP. In
total, 25/42 (60%) samples showed reduced expression
level compared to the normal bone samples.
The protein level was investigated by western blotting
(Figure 2A). Of the samples with loss of copy number, 2/
16 had detectable levels of the LSAMP protein, shown
by a band of approximately 62 kDa, corresponding to
the size reported by others (60–68 kDa) [23,24]. Of the
samples with normal copy number, 3/16 had detectable
levels of the LSAMP protein, whereas of the samples
with gain of copy number, the protein was detected in 4/
10 samples. In total, the protein was detected in one
clinical sample and eight cell lines. There was no clear
correlation between mRNA level and protein level, as
some samples with relatively high mRNA level had un-
detectable protein levels.
We have previously shown an association between low
expression of LSAMP and poor survival [6]. Of the sam-
ples investigated in this study (n = 18, of which 10 xeno-
grafts and 8 clinical samples), although not statistically
significant (p = 0.083, Mantel-Cox test), there was a
trend towards poorer survival in patients with loss of
LSAMP copy number (Figure 2B). There was no associ-
ation between the expression of LSAMP and overall sur-
vival (Figure 2C) (p = 0.486).
Restoring the expression of LSAMP
The cell line IOR/OS14 was chosen to ectopically reex-
press LSAMP as it has a homozygous deletion of the
gene [6]. In total, 23 clones transfected with LSAMP
ORF were assayed for levels of ectopic LSAMP mRNA
and protein, and compared to two control clones (back-
bone vector). All 23 clones had detectable levels of the
LSAMP mRNA, but only 12 showed detectable though
variable protein levels (Figure 3A). The clones were
categorized to whether they had undetectable, low,
medium or high levels of the LSAMP protein (Figure 3A).
Low protein levels were most comparable to the endogen-
ous protein levels found in osteosarcoma samples investi-
gated (Figure 2A) and the non-cancerous mesenchymal
cell line HEPM (Figure 3B). By immunofluorescence
confocal microscopy, the ectopically expressed LSAMP
protein was shown to be localized to the cell membrane
(Figure 3C), which is consistent with LSAMP being a
membrane protein [25].
Ectopic expression of LSAMP delays tumor formation
in vivo
The clones with low levels of the LSAMP protein (LSAMP
#7, #9 and #21) were chosen for functional characterization
and compared to cells without LSAMP-expression (Ctrl
#1, #2 and non-transfected cells). The proliferation rate of
the clones with the LSAMP protein was significantly re-
duced 15-20% compared to the cells without LSAMP-ex-
pression (Figure 4A) (p = 0.004, Mann–Whitney test).
With exception of non-transfected cells, the same
clones were used for investigating the in vivo tumor-
forming ability of the cells. Each clone was injected into
both flanks of six mice, giving a total of 12 potential
tumor sites, with the exception of LSAMP #9, which
was injected into three mice and thus had a total of six
potential tumor sites. Time until tumor appearance is
shown by a Kaplan-Meier plot in Figure 4B, showing
that cells with the LSAMP protein have a significant de-
layed tumor formation compared to the clones without
LSAMP-expression (p = 0.002, Mantel-Cox test).
In addition, other cancer phenotypes were investigated.
Neither cell cycle distribution (Additional file 3: Figure S2)
nor apoptosis (Additional file 4: Figure S3) identified by
flow cytometry, or the migration rate using time-lapse
photography in the IncuCyte (Additional file 5: Figure S4),
were shown to be affected by the expression of LSAMP.
As the parental cell line IOR/OS14 has been shown to suc-
cessfully differentiate towards the adipogenic and osteo-
genic lineage [26], differences in differentiation capabilities
were investigated. The degree of differentiation was not
affected by the expression of LSAMP (data not shown).
Ectopic expression of LSAMP upregulates HES1, CTAG2
and KLF10
To identify possible mechanisms involved in tumor
suppression by LSAMP, changes in gene expression in
response to LSAMP reexpression were investigated by
mRNA expression profiling. Seven clones with different
levels of the LSAMP protein (LSAMP #7, #9 #11, #16,
#17, #18 and #21) were compared to the two control
clones (Ctrl #1 and #2). The analysis revealed that com-
pared to the average expression of the two control
clones, three genes, in addition to LSAMP, were
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differentially expressed in all seven clones (Figure 5A).
These genes were hairy and enhancer of split 1 (HES1),
cancer/testis antigen 2 (CTAG2) and kruppel-like factor
10 (KLF10), which were all overexpressed compared to
the controls, and the upregulation was validated by qRT-
PCR (Figure 5B). In addition, one clone (LSAMP #1) ex-
pressing LSAMP mRNA, but without detectable levels of
the protein (Figure 2A), was included. Interestingly, this
clone had similar levels to the two control clones, sup-
porting that the presence of the LSAMP protein is the
cause for the induction of these genes.
Of the 42 samples tested for LSAMP protein (Figure 2A),
30 had available mRNA expression profiling data ([21]
and Kresse et al., unpublished). The expression levels
of the genes LSAMP, HES1, CTAG2 and KLF10 were
compared between samples with detectable (n = 7) and
undetectable (n = 23) levels of the LSAMP protein. For
LSAMP, the expression was higher in the samples with
LSAMP protein (Additional file 6: Figure S5 A, p =
0.026, Mann–Whitney test). For HES1, CTAG2 and
KLF10, no differences in the median expression levels be-
tween the two groups were observed (Additional file 6:
Figure S5).
Discussion
Osteosarcomas are cytogenetically complex malignan-
cies, with a vast number of DNA copy number aberra-
tions. A recurrent deletion within 3q13.31 has been
Figure 3 LSAMP reexpression. A: LSAMP expression and protein level in clones with ectopic expression of LSAMP. The expression level was
measured using qRT-PCR, using two probes (located in exon junction 1–2 and 6–7). The corresponding LSAMP protein level was determined
using western blot, with β-actin as loading control. The clones are sorted according to whether they have undetectable, low, medium or high
protein levels. B: Comparison of the endogenous levels of the LSAMP protein in the non-cancerous cell line HEPM and seven LSAMP-expressing
clones with increasing amount of protein. C: Subcellular location of the ectopically expressed LSAMP protein in LSAMP-expressing cells (LSAMP
#16) and control cells (Ctrl #1) determined using immunofluorescence confocal microscopy. Red color represents stain for anti-LSAMP-antibody,
blue represents staining of the nuclei (DAPI).
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identified [6,13,14,27,28]. This deletion has so far only
been described in one other cancer type [20], indicating
that it is highly specific to osteosarcomas. This specifi-
city argues that the deletion is not due to a fragile site
and strongly suggests involvement of this region in
osteosarcoma development. Thus, the deleted region is
likely to contain sequences preventing or retarding
osteosarcoma development or progression.
The simplest interpretation would be that the region
harbors one or more tumor suppressor genes. Concor-
dantly, three genes located within the deleted region have
been proposed to have tumor suppressive functions in
osteosarcomas: LSAMP [6,12-14], LSAMP-AS3 [13] and
LSAMP-AS4 [13]. However, our results showed either no
or low expression levels of LSAMP-AS3 and LSAMP-AS4
in all the samples investigated, including the control
samples. The control samples originated from osteoblastic
cultures, bone, brain and smooth muscle. In addition, we
included the Universal Human Reference RNA, which is a
pool of RNA from ten different human cell lines repre-
senting various cancer types, excluding osteosarcoma. As
neither LSAMP-AS3 nor LSAMP-AS4 were expressed in
any of these control samples, it is reasonable to argue that
the low or lack of expression in the osteosarcoma samples
is not due to inactivation, but a normal state for both non-
cancerous and cancerous cells. The other genes located
within the deleted region (only annotated by ENSEMBL,
supported by GENCODE/ENCODE) have been annotated
only recently, and was thus not investigated in this study.
However, stranded total RNA-sequencing data of 10
osteosarcoma cells lines and the non-tumorigenic cell line
iMSC#3 (both undifferentiated and with osteogenic differ-
entiation), showed no detectable expression corresponding
to any of these genes (Meza-Zepeda et al., unpublished).
Figure 5 Differential gene expression: A) Venn diagram showing the number of differentially expressed genes in the clones with low (LSAMP
#7, #9 and #21), medium (LSAMP #11 and #17) and high (LSAMP #16 and #18) LSAMP protein level compared to the average of the two control
clones (Ctrl #1 and #2). B: Validation of the mRNA expression profiling results for the genes HES1, CTAG2 and KLF10, determined by qRT-PCR. Fold
change is compared to the average of the two control clones (Ctrl #1 and #2).
Figure 4 Proliferation rate and in vivo tumor growth. A: Relative proliferation rate of LSAMP-expressing cells (LSAMP #7, #9 and #21)
compared to cells without LSAMP-expression (Ctrl #1 and #2 and non-transfected cells). The experiment was performed twice. The midline is the
median observation, and the whiskers represent the total spread of the observations. The difference was tested statistically significant with a
Mann–Whitney test (p = 0.004). B: In vivo tumorigenicity measured as time until tumor appearance, represented by a Kaplan-Meier plot. The
difference between the LSAMP-expressing cells (LSAMP #7, #9 and #21) and the cells without LSAMP-expression (Ctrl #1 and #2) was tested
statistically significant by a Mantel-Cox test (p = 0.002).
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Even though we cannot exclude that other genes within
the deleted region are important for the development of
osteosarcomas, several lines of evidence indicate that
LSAMP is a tumor suppressor gene and the target for the
deletion in 3q13.31. DNA methylation of the promoter
region has been described, indicating that LSAMP is epi-
genetically inactivated in cancer [6,17], and absent or low
expression of LSAMP has been reported to be a frequent
characteristic of osteosarcomas [6,12-14]. We have previ-
ously shown that expression of LSAMP is associated with
poor survival in a larger panel of osteosarcoma patients
[6], and it has also been shown in patients with epithelial
ovarian cancer [15]. In this study, we saw a trend towards
poorer survival in patients with loss of LSAMP copy
number, although not statistically significant, possibly due
to the limited sample size (n = 18). Overexpression of
LSAMP was shown to inhibit proliferation in a renal cell
carcinoma cell line [17], whereas depletion of LSAMP pro-
moted cell proliferation in osteoblasts [13]. These observa-
tions are consistent with the function of LSAMP to be a
tumor suppressor gene. Our results add to these evidences
as we showed reduced proliferation rate in vitro and inhib-
ited tumor growth in vivo when the expression of LSAMP
was restored.
By western blotting, we investigated whether the
LSAMP transcript was translated, which to our know-
ledge has not been done in tumor samples. However, we
did not find a clear correlation between the mRNA level
of LSAMP and the protein level in our samples. Interest-
ingly, one study has shown that in osteosarcomas with
high mRNA levels of LSAMP, a premature termination
codon was detected [14]. It is tempting to speculate that
this is the cause for the apparent lack of translation in
some of the samples. However, the premature termin-
ation codon was not found in any of 19 osteosarcoma
cell lines based on available RNA-sequencing data
(Meza-Zepeda et al., unpublished), indicating that this is
not a frequent event of regulation in osteosarcomas.
Taking into account that 11/23 clones transfected with
LSAMP ORF failed to translate the transcripts to detect-
able levels, there could also be post-transcriptional
regulation of LSAMP, even though these transcripts are
lacking features of the endogenous mRNA. Also, as only
the clones with detectable levels of the LSAMP protein
had upregulated HES1, CTAG2 and KLF10, our results
indicate that the LSAMP protein is indirectly affecting
the upregulation of these genes. However, it is also pos-
sible that the cells upregulated one or more of these
genes to be able to grow in the presence of the LSAMP
protein. On the other hand, there were no differential
expression of these genes between the investigated sam-
ples with (n = 7) and without (n = 23) detectable levels
of the LSAMP protein, based on mRNA expression
profiling data ([21], Kresse et al., unpublished). This
discrepancy could be explained by the relatively small
size of the cohort with LSAMP protein. However,
LSAMP is one of four IgLONs [29], which are cell adhe-
sion molecules that function as dimers, referred to as
Diglons [30]. LSAMP has been shown to only function
as heterodimers with either Opioid-binding cell adhe-
sion molecule (OBCAM) or Neurotrimin (NTM) [30]. If
the dimerization partner of LSAMP is not present, it
would most likely not function properly. OBCAM was not
expressed in any of the investigated samples (n = 7 with
LSAMP protein, n = 23 without LSAMP protein), but
NTM was expressed at different levels. Furthermore, the
non-transfected parental cell line IOR/OS14 had among
the highest expression levels of NTM and ranking as num-
ber 11 out of the 30 samples (data not shown). Also, the
majority of the cohort with LSAMP protein had low ex-
pression of NTM. Thus, it is possible that we do not find
an upregulation of HES1, CTAG2 and/or KLF10 in these
samples due to the lack of expression of a LSAMP
dimerization partner.
HES1, CTAG2 and KLF10 have all been shown to play a
role in cancer biology. HES1 has been suggested to have
both oncogenic and tumor suppressive functions [31,32],
whereas KLF10 has been suggested to be a tumor suppres-
sor gene [33,34]. CTAG2 is mainly expressed in the repro-
ductive organs, in addition to a variety of cancers [35-37].
To our knowledge, the function of CTAG2 is not known,
but both HES1 and KLF10 have been shown to be in-
volved in bone biology. HES1 has been shown to bind to
bone-specific promoters together with the runt-related
transcription factor 2 (RUNX2) and the retinoblastoma
protein (RB) [38]. KLF10 has been shown to have an im-
pact on the proliferation of osteoblasts, osteoclasts and
osteosarcoma cells [39,40], which could be the cause for
the observed reduced proliferation rate. In a recent study,
LSAMP clustered together with pro-apoptotic genes when
gene expression changes of osteosarcoma cell lines were
analyzed after induction of apoptosis [41]. Furthermore,
depletion of LSAMP in osteoblasts had an effect on the
expression of the proapoptotic genes BCL2 and BimEL
[13]. Although apoptosis could be a possible mechanism
for LSAMP to suppress or delay tumors formation, we did
not find evidence of apoptosis in our clones with LSAMP-
reexpression. This is consistent with another study where
LSAMP was overexpressed in a clear cell renal cell carcin-
oma cell line without any evidence of apoptotic cells [17].
The high frequency of the deletion in 3q13.31 and the
specificity for osteosarcomas strongly suggest a functional
role for this region and that it harbors a tumor suppressor
gene important for the development of osteosarcomas.
Our results indicate that among the genes investigated in
3q13.31, LSAMP is the target for the deletion. The func-
tion of HES1 and KLF10 in bone biology also implies a
function for these genes in osteosarcoma development.
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Furthermore, the reduced proliferation rate in vitro and
inhibited tumor growth in vivo is further pointing to a
tumor suppressor function of LSAMP.
Conclusions
We have identified a frequent deletion in osteosarcomas
and shown LSAMP to be the target gene within the dele-
tion. We believe that LSAMP is a tumor suppressor gene
in osteosarcomas and that LSAMP suppress tumors by
reducing the proliferation rate of cancer cells, possibly
through upregulation of one or more of the genes HES1,
CTAG2 and KLF10.
Materials and methods
Samples
Clinical data for all osteosarcoma and control samples
are listed in Additional file 1: Table S1.
Human osteosarcoma clinical samples (n = 39) were
analyzed, of which 13 were primary or metastatic sam-
ples collected at the Norwegian Radium Hospital, Oslo,
Norway and 26 were grown subcutaneously in immuno-
deficient mice as xenografts (suffix x), obtained either
from the Norwegian Radium Hospital (n = 15) or the
Department of Pathology, University of Valencia, Spain
(n = 11). All tumors were diagnosed according to the
current World Health Organization classification [42].
The informed consent used and the collection of sam-
ples were approved by the Ethical Committee of South-
ern Norway, Project S-06133 or the Institutional Ethical
Committee of the University of Valencia. The samples
were collected immediately after surgery, snap frozen in
liquid nitrogen and stored at −80°C. The establishment
and passing of xenografts were in accordance with na-
tional and institutional animal care guidelines.
In addition, osteosarcoma cell lines (n = 21) were ana-
lyzed. These were: G-292, 143B, HOS, MNNG/HOS, MG-
63, OSA (SJSA-1), Saos-2, U-2 OS (n = 9) (American Type
Culture Collection; ATCC), HAL, KPD, MHM, OHS
(n = 4) (The Norwegian Radium Hospital), IOR/OS9, IOR/
OS10, IOR/OS14, IOR/OS15, IOR/OS18, IOR/MOS, IOR/
SARG (n = 7) (Istituto Ortopedico Rizzoli, Bologna, Italy),
ZK-58 (Heinrich-Heine University, Düsseldorf, Germany)
and CAL 72 (University College London, London, UK).
The cells were grown in RPMI 1640 or DMEM (both
Lonza) supplemented with 10% FBS (Fisher Scientific) and
GlutaMAX (Life Technologies), at 37°C in a humidified
atmosphere with 5% CO2. All cell lines were tested for
mycoplasma and found negative, and authenticated as
previously described [43].
Control samples (n = 15) were also analyzed. Normal
long bone samples were purchased from Capital Biosci-
ences (n = 2) or obtained from amputations of cancer
patients at the Norwegian Radium Hospital (n = 4) or
University College London (n = 1). The normal bone was
collected as distant as possible from the tumor site, and
SNP array confirmed normal DNA copy number. Pri-
mary osteoblast cultures (n = 2) isolated from human
calvaria of different donors were purchased from Scien-
Cell Research Laboratories. The non-tumorigenic cell
lines (n = 3) HEPM, hFOB (both ATCC) and iMSC#3
were included; the latter being an immortalized human
bone marrow-derived mesenchymal stromal cell line
established in our laboratory (Skårn et al., unpublished).
Commercial normal RNA samples (n = 3) were used,
one from brain tissue (Life Technologies), one from
smooth muscle (Clonetech Laboratories) and Universal
Human Reference RNA (Agilent Technologies).
DNA copy number and expression level
DNA copy number was determined either by high-
resolution aCGH or the real-time PCR based assay Taq-
Man DNA Copy Number Assay (Life Technologies), as
previously described [21]. aCGH was performed using
the Affymetrix Genome-Wide Human SNP Array 6.0
(Affymetrix) and DNA copy number analysis was per-
formed using the Nexus software (BioDiscovery), as pre-
viously described [21]. Expression level was determined
using TaqMan Gene Expression Assays (Life Technolo-
gies) as previously described [6], and is hereafter referred
to as qRT-PCR (quantitative real-time reverse transcrip-
tion PCR). The expression level of the clinical samples
and cell lines was analyzed as previously described [6],
and the expression level of the clones was analyzed using
the 2-ΔΔCt-method [44], with TATA box binding protein
(TBP) as an endogenous reference. The assays used and
their respective ID number are listed in Additional file 7:
Table S2.
Western blotting
Total protein lysate was run on a 4-12% Bis-Tris NuPAGE
precast gel (Life Technologies) and transferred onto a
PVDF membrane (Millipore). The antibodies used and
their respective conditions are listed in Additional file 8:
Table S3. The proteins were visualized using SuperSignal
West Duration Substrate (Thermo Scientific).
Vector construction and transfection
The LSAMP expression vector was constructed using
Gateway Technology (Life Technologies), recombining a
vector containing LSAMP open reading frame (ORF) (ID
number OCAAo5051A0349D, imaGenes) with pT-REx-
DEST30 (Life Technologies). The cell line IOR/OS14 was
stably transfected with either the expression vector
(named LSAMP ORF) or the backbone vector using Lipo-
fectamine 2000 (Life Technologies). Selection was per-
formed using 450 μg/ml Geneticin (Life Technologies) for
14 days, after which the concentration was reduced to
225 μg/ml.
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Immunofluorescence confocal microscopy
The anti-LSAMP antibody was a kind gift from Dr.
Aurea F. Pimenta, Vanderbilt University, Nashville, USA.
The cells were grown on coverslips and fixed in 10% for-
malin solution (Sigma-Aldrich), rinsed in PBS and
blocked in 5% FBS in PBS for 30 min before incubation
with the antibody in 1:100 dilution in 5% FBS for 1 h at
RT. After incubation, the cells were washed 3 × 5 min in
5% FBS and incubated in a 1:200 dilution of anti-mouse-
IgG/Cy3 (Jackson ImmunoResearch Laboratories) for
30 min at RT. The cells were then washed 3 × 5 min in
5% FBS and rinsed in dH2O. The nuclei were stained
using ProLong Gold Antifade Reagent with DAPI (Life
Technologies). The fluorescence was visualized using a
Zeiss LSM 510 confocal microscope (Zeiss) and pictures
were taken of thin single plane sections.
Proliferation rate
Proliferation rate was measured using the CellTiter 96
AQueous One Solution Cell Proliferation Assay (MTS)
(Promega). Cells stably transfected with LSAMP ORF or
the backbone vector were seeded in quadruplicates in a
96-well plate with 10,000 cells per well in 100 μl medium.
The cell viability was measured after 96 h.
In vivo tumorigenicity
Animal experiments were performed according to proto-
cols approved by the National Animal Research Authority
in compliance with the European Convention of the
Protection of Vertebrates Used for Scientific Purposes (ap-
proval ID 1499 and 3275, http://www.fdu.no/). The experi-
ments were performed as previously described [45].
Apoptosis and cell cycle distribution
Apoptosis and cell cycle distribution were investigated
using flow cytometry. For apoptosis, APO-BRDU (TUNEL)
assay (Life Technologies) was performed, according to the
manufacturer’s instructions. For investigation of cell cycle
distribution, 2*106 cells were harvested and resuspended in
200 μl ice-cold PBS and added to 4 ml ice-cold ethanol and
incubated on ice for 45 min. Then, 6 ml of ice-cold staining
buffer (SB: 0.5% BSA in PBS) was added, and the cells were
centrifuged at 300 × g, at 4°C for 5 min. The pellet was re-
suspended in 1 ml SB and the centrifugation repeated. The
cells were resuspended in 300 μl SB containing 2 μg/ml
Hoechst 33342 (Sigma-Aldrich). For both assays, the LSR II
UV Laser (BD Bioscience) was used, and the data was ana-
lyzed using FlowJo v8.8.7 software (Tree Star).
Migration rate
The migration assay was performed using the IncuCyte
system (Essen Bioscience).
Differentiation
Adipogenic differentiation and Oil red O staining were
performed as previously described [46], except that cells
were seeded at a density of 3,000 cells/cm2.
For the osteogenic differentiation, the cells were
seeded at a density of 4,500 cells/cm2. Osteogenesis was
initiated with osteogenic induction medium containing
10 nM Dexamethasone, 3.5 mM β-Glycerolphosphate and
66.7 μM Ascorbic acid 2-phosphate (all from Sigma-
Aldrich). The osteogenic induction medium was replaced
every third day. To estimate the degree of differentiation,
the wells were washed with PBS, fixed in ice-cold 70%
ethanol for 1 h at 4°C, washed with ddH2O and subse-
quently stained with 0.4% Alizarin Red S solution (w/v,
pH 4.2; Sigma-Aldrich) for 10 min at RT. The staining so-
lution was removed by washing the cells 5 × in ddH2O,
followed by a 15 min wash in PBS. The cells were dehy-
drated with 70% ethanol, followed by absolute ethanol and
air-dried. This procedure was performed after 0, 14, 21
and 28 days of differentiation, respectively.
mRNA expression profiling
RNA was isolated using the miRNeasy Mini Kit (QIA-
GEN GmbH). The RNA integrity was evaluated using
the Agilent 2100 Bioanalyzer and the RNA nano 6000
kit (Agilent Technologies). For each sample, 500 ng of
total RNA was used to make biotin-labeled and ampli-
fied cRNA with the Illumina TotalPrep Amplification
Kit (Life Technologies). cRNA was hybridized to Illumi-
na’s HumanHT-12 v4 Expression BeadChip as previ-
ously described [47]. Expression values were annotated
using the file HumanHT-12_V4_O_R2_15002873_B.bgx
(Illumina). The expression data was quantile normalized
[48] in GenomeStudio Gene Expression module v1.9
(Illumina) and log2-transformed, and a rank product
analysis [49] was performed in J-Express [50] using a q-
value < 0.05 to identify significant changes of gene ex-
pression. The dataset has been deposited in the GEO
data repository (www.ncbi.nlm.nih.gov/geo/, accession
number GSE52089).
Statistical analysis
Statistical analyses were performed using SPSS version 20.
A p-value < 0.05 was regarded as statistically significant.
Additional files
Additional file 1: Table S1. Clinical data for osteosarcoma samples and
control samples.
Additional file 2: Figure S1. Expression level of other genes in 3q13.31.
The expression of LSAMP-AS1, LSAMP-AS3 and LSAMP-AS4 was
investigated by qRT-PCR. The different expression levels are shown as
relative percent to an endogenous reference gene (TBP) within the same
sample. UHR: Universal Human Reference RNA, OB: Osteoblast.
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Additional file 3: Figure S2. Cell cycle distribution. A representative
figure showing cell cycle distribution investigated by flow cytometry.
A and B: Two clones with low levels of the LSAMP protein (A: #7 and B:
#21), C and D: two control clones (C: #1 and D: #2) and E: non-
transfected cells were included in the analysis. The experiment was
performed twice.
Additional file 4: Figure S3. Apoptosis. A representative figure
showing apoptosis investigated by flow cytometry. Included in the
analysis were A: Negative control cells, B: Positive control cells, C-E: Three
clones with low levels of the LSAMP protein (C: #7, D: #9 and E: #21),
F and G: two control clones (F: #1 and G: #2) and H: non-transfected
cells. The experiment was performed thrice.
Additional file 5: Figure S4. Migration rate. A representative figure
showing the migration rate investigated by time-lapse photography
using the IncuCyte. The migration of two clones with low levels of the
LSAMP protein (#9 and #21), two control clones (#1 and #2) and
non-transfected cells were monitored as relative wound density over
time (h). The experiment was performed twice. Error bars represent
standard deviations of the technical replicates (n = 6).
Additional file 6: Figure S5. Expression levels of LSAMP, HES1, CTAG2
and KLF10 in samples with and without LSAMP protein. Shown are the
expression levels of A: LSAMP, B: HES1, C: CTAG2 and D: KLF10 in samples
with detectable (n = 7) and undetectable levels (n = 23) of the LSAMP
protein. The expression level of CTAG2 was detected by two probes in
the bead array (probe ID ILMN 1787578 and ILMN 1715347), and shown
in C is the median expression level of the two probes. The expression
level of KLF10 was detected by three probes (probe ID ILMN 1720080,
ILMN 1659122 and ILMN 167594), and shown in D is the median
expression level of the three probes.
Additional file 7: Table S2. Overview TaqMan assays.
Additional file 8: Table S3. Overview antibodies used for western
blotting.
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